Long-term impact of chronic kidney disease in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: the HORIZONS-AMI (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction) trial.

[1]  R. Elosua,et al.  Relation between renal function and outcomes in patients with non-ST-segment elevation acute coronary syndrome: real-world data from the European Public Health Outcome Research and Indicators Collection Project. , 2010, Archives of internal medicine.

[2]  K. Alexander,et al.  Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non–ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease: A Report From the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network R , 2010, Circulation.

[3]  A. Kastrati,et al.  Prognostic value of kidney function in patients with ST-elevation and non-ST-elevation acute myocardial infarction treated with percutaneous coronary intervention. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  B. Gersh,et al.  Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial , 2009, The Lancet.

[5]  W. Markiewicz,et al.  The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. , 2009, Kidney international.

[6]  S. Pocock,et al.  Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. , 2009, JACC. Cardiovascular interventions.

[7]  Deepak L. Bhatt,et al.  The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale. , 2008, American heart journal.

[8]  B. Gersh,et al.  Bivalirudin during primary PCI in acute myocardial infarction. , 2008, The New England journal of medicine.

[9]  J. Ware,et al.  Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. , 2007, JAMA.

[10]  David L. Brown,et al.  The impact of advanced chronic kidney disease on in‐hospital mortality following percutaneous coronary intervention for acute myocardial infarction , 2007, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[11]  W. Desmet,et al.  Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial (vol 292, pg 696, 2004) , 2006 .

[12]  W. Gibler,et al.  Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. , 2006, The American journal of medicine.

[13]  G. Hillis,et al.  Renal Function and Outcome From Coronary Artery Bypass Grafting: Impact on Mortality After a 2.3-Year Follow-Up , 2006, Circulation.

[14]  E. Topol,et al.  The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial. , 2005, American heart journal.

[15]  E. Topol,et al.  Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). , 2005, The American journal of cardiology.

[16]  P. Serruys,et al.  Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents. , 2005, The American journal of cardiology.

[17]  M. Tonelli,et al.  The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease. , 2004, Journal of the American College of Cardiology.

[18]  E. Topol,et al.  Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. , 2004, JAMA.

[19]  Deepak L. Bhatt,et al.  Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. , 2003, The American journal of cardiology.

[20]  A. Jaffe,et al.  Acute Myocardial Infarction and Renal Dysfunction: A High-Risk Combination , 2002, Annals of Internal Medicine.

[21]  M. Reed,et al.  Clinical Pharmacology of Bivalirudin , 2002, Pharmacotherapy.

[22]  S. Snapinn,et al.  Benefits and Safety of Tirofiban Among Acute Coronary Syndrome Patients With Mild to Moderate Renal Insufficiency: Results From the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Trial , 2002, Circulation.

[23]  M. Bell,et al.  The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. , 2002, Journal of the American College of Cardiology.

[24]  D. Goldsmith,et al.  Coronary artery disease in uremia: Etiology, diagnosis, and therapy. , 2001, Kidney international.

[25]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[26]  M. Pencina,et al.  In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry. , 2009, JACC. Cardiovascular interventions.

[27]  Christopher T. Chan,et al.  Impact of renal insufficiency on outcome after contemporary percutaneous coronary intervention. , 2006, American heart journal.

[28]  W. Geerts,et al.  Anticoagulant Use in Patients with Chronic Renal Impairment , 2005, American journal of cardiovascular drugs : drugs, devices, and other interventions.

[29]  G. Barsotti,et al.  Bleeding and thrombosis in chronic uremia. , 1997, Nephron.

[30]  A. Cupisti,et al.  Increased thrombin generation in patients with chronic renal failure , 1997, International journal of clinical & laboratory research.

[31]  E. Beutner,et al.  Report of a WHO Scientific Group (Part 3 of 3) , 1973 .

[32]  Nutritional anaemias. Report of a WHO scientific group. , 1968, World Health Organization technical report series.